Daniel DiRenzo

1.5k total citations · 1 hit paper
38 papers, 1.0k citations indexed

About

Daniel DiRenzo is a scholar working on Physiology, Oncology and Molecular Biology. According to data from OpenAlex, Daniel DiRenzo has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Daniel DiRenzo's work include Adenosine and Purinergic Signaling (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Nanoplatforms for cancer theranostics (7 papers). Daniel DiRenzo is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Nanoplatforms for cancer theranostics (7 papers). Daniel DiRenzo collaborates with scholars based in United States, Sweden and Canada. Daniel DiRenzo's co-authors include Nicholas J. Leeper, Thomas Quertermous, Clint L. Miller, Vivek Nanda, Ulf Hedin, Lars Mäegdefessel, Andrew J. Connolly, Yoko Kojima, Jianqin Ye and Mete Civelek and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Daniel DiRenzo

35 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

2016 500 citations Clint L. Miller, Daniel DiRenzo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel DiRenzo United States	15	478	474	170	157	121	38	1.0k
Curran Murphy United States	8	594 1.2×	344 0.7×	146 0.9×	171 1.1×	241 2.0×	12	1.2k
Hao‐Chen Wang Taiwan	15	420 0.9×	253 0.5×	342 2.0×	92 0.6×	190 1.6×	30	934
Kari Vaahtomeri Finland	16	662 1.4×	189 0.4×	482 2.8×	189 1.2×	152 1.3×	21	1.2k
W. Christopher Shelley United States	18	669 1.4×	444 0.9×	110 0.6×	98 0.6×	103 0.9×	42	1.4k
Defeng Deng United States	18	703 1.5×	280 0.6×	476 2.8×	218 1.4×	362 3.0×	29	1.3k
Charlotte E. Edling United Kingdom	14	606 1.3×	136 0.3×	273 1.6×	141 0.9×	124 1.0×	32	1.0k
Mahnaz Bonrouhi Germany	14	493 1.0×	210 0.4×	114 0.7×	134 0.9×	127 1.0×	21	947
Joel Chappell United Kingdom	12	580 1.2×	331 0.7×	73 0.4×	116 0.7×	163 1.3×	18	976
Cheryl A. Doughty United States	9	561 1.2×	291 0.6×	159 0.9×	44 0.3×	117 1.0×	11	907
Mingming Fang China	21	711 1.5×	176 0.4×	143 0.8×	81 0.5×	195 1.6×	33	1.0k

Countries citing papers authored by Daniel DiRenzo

Since Specialization

Citations

This map shows the geographic impact of Daniel DiRenzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel DiRenzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel DiRenzo more than expected).

Fields of papers citing papers by Daniel DiRenzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel DiRenzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel DiRenzo. The network helps show where Daniel DiRenzo may publish in the future.

Co-authorship network of co-authors of Daniel DiRenzo

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel DiRenzo. A scholar is included among the top collaborators of Daniel DiRenzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel DiRenzo. Daniel DiRenzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kim, Ji Yun, José Luís Braga de Aquino, Chunyou Mao, et al.. (2024). 52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial. Regular and Young Investigator Award Abstracts. A58–A58.

2.

Kim, Ji Yun, Ning Wang, Benjamin R. Weeder, et al.. (2024). Abstract C007: Quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial. Cancer Research. 84(17_Supplement_2). C007–C007. 1 indexed citations

3.

Marubayashi, Sachie, Bindi Patel, Jenna L. Jeffrey, et al.. (2022). Abstract 256: Dual A2aR/A2bR antagonism with etrumadenant (AB928) eliminates the suppressive effects of adenosine on immune and cancer cells in the tumor microenvironment. Cancer Research. 82(12_Supplement). 256–256. 2 indexed citations

4.

Le, Thuc, Evan R. Abt, Woosuk Kim, et al.. (2020). Abstract 6649: Inhibiting adenosine signaling and KRAS enhances the effect of α-PD-1 therapy in a KRASG12C/TP53R172H/+ pancreatic cancer model. Cancer Research. 80(16_Supplement). 6649–6649. 1 indexed citations

5.

Le, Thuc, Akshata R. Udyavar, Woosuk Kim, et al.. (2020). Abstract A46: CD73 inhibition enhances the effect of anti-PD-1 therapy on KRAS-mutated pancreatic cancer model. Cancer Immunology Research. 8(3_Supplement). A46–A46. 2 indexed citations

6.

DiRenzo, Daniel, Devika Ashok, Jenna L. Jeffrey, et al.. (2020). Abstract A10: The dual A2aR/A2bR antagonist AB928 reverses adenosine-mediated immune suppression and inhibits tumor growth in vivo. Cancer Immunology Research. 8(4_Supplement). A10–A10. 2 indexed citations

7.

DiRenzo, Daniel, Joanne B.L. Tan, Dillon H. Miles, et al.. (2019). Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. Cancer Immunology Research. 7(2_Supplement). A162–A162. 7 indexed citations

8.

Udyavar, Akshata R., Daniel DiRenzo, Devika Ashok, et al.. (2019). Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers. Cancer Research. 79(13_Supplement). 4980–4980. 3 indexed citations

9.

Udyavar, Akshata R., Daniel DiRenzo, Devika Ashok, et al.. (2019). Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers. Immunology. 4980–4980. 1 indexed citations

10.

Zhu, Yichen, Toshio Takayama, Bowen Wang, et al.. (2017). Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by Resveratrol. Scientific Reports. 7(1). 41916–41916. 24 indexed citations

11.

Jiang, Mei, Ana Clara P. Azevedo‐Pouly, Tye Deering, et al.. (2016). MIST1 and PTF1 Collaborate in Feed-Forward Regulatory Loops That Maintain the Pancreatic Acinar Phenotype in Adult Mice. Molecular and Cellular Biology. 36(23). 2945–2955. 33 indexed citations

12.

Pjanic, Milos, Clint L. Miller, Robert Wirka, et al.. (2016). Genetics and Genomics of Coronary Artery Disease. Current Cardiology Reports. 18(10). 102–102. 23 indexed citations

13.

DiRenzo, Daniel, Xudong Shi, Sarah Franco, et al.. (2016). A crosstalk between TGF-β/Smad3 and Wnt/β-catenin pathways promotes vascular smooth muscle cell proliferation. Cellular Signalling. 28(5). 498–505. 88 indexed citations

14.

DiRenzo, Daniel, Xu Shi, Sarah Franco, et al.. (2015). Abstract 227: TGF-β/Smad3 Promotes Smooth Muscle Cell De-differentiation and Proliferation Through Crosstalk with the Wnt/β-Catenin Pathway. Arteriosclerosis Thrombosis and Vascular Biology. 35(suppl_1). 1 indexed citations

15.

Takayama, Toshio, Xudong Shi, Bowen Wang, et al.. (2015). A Murine Model of Arterial Restenosis: Technical Aspects of Femoral Wire Injury. Journal of Visualized Experiments. 15 indexed citations

16.

Shi, Xudong, Stephen Seedial, Yi Si, et al.. (2014). TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell Death and Disease. 5(7). e1317–e1317. 40 indexed citations

17.

Shi, Xudong, Daniel DiRenzo, Lian‐Wang Guo, et al.. (2014). TGF-β/Smad3 Stimulates Stem Cell/Developmental Gene Expression and Vascular Smooth Muscle Cell De-Differentiation. PLoS ONE. 9(4). e93995–e93995. 32 indexed citations

18.

DiRenzo, Daniel, David A. Hess, Barbara Damsz, et al.. (2012). Induced Mist1 Expression Promotes Remodeling of Mouse Pancreatic Acinar Cells. Gastroenterology. 143(2). 469–480. 50 indexed citations

19.

Coon, Brian G., Daniel DiRenzo, Stephen F. Konieczny, & R. Claudio Aguilar. (2011). Epsins’ novel role in cancer cell invasion. Communicative & Integrative Biology. 4(1). 95–97. 11 indexed citations

20.

Garside, Victoria C., et al.. (2010). MIST1 regulates the pancreatic acinar cell expression of Atp2c2, the gene encoding secretory pathway calcium ATPase 2. Experimental Cell Research. 316(17). 2859–2870. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact